SFX by Ex Libris Inc.

Title:	Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
Source:	Science [0036-8075] Sievers, Q L yr:2018

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Haapaniemi, E. "CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response." Nature Medicine 24.7 (2018): 927-930.
description	2.	Ihry, Robert J. "p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells." Nature Medicine 24.7 (2018): 939-946.
description	3.	Ding, Q. "Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing." Circulation research 115.5 (2014): 488-92.
description	4.	Yang, W. "CRISPR/Cas9: Implications for Modeling and Therapy of Neurodegenerative Diseases." Frontiers in Molecular Neuroscience 9 (2016): 30-30.
description	5.	Wang H, H. "CRISPR/Cas9 in Genome Editing and Beyond." Annual Review of Biochemistry 85.1 (2016): 227-264.
description	6.	Zhai, X. "No ethical divide between China and the West in human embryo research." Developing world bioethics 16.2 (2016): 116-120.
description	7.	Dow, Lukas E. "CRISPR: Stressed about p53?" Trends in molecular medicine. 24.9: 731-733.
description	8.	Zhang, Y. "Poly(GR) impairs protein translation and stress granule dynamics in C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis." Nature Medicine 24.8 (2018): 1-7.
description	9.	Desjardins, A. "Recurrent Glioblastoma Treated with Recombinant Poliovirus." The New England Journal of Medicine 379.2 (2018): 150-161.
description	10.	Li, Hongmei L. "Precise Correction of the Dystrophin Gene in Duchenne Muscular Dystrophy Patient Induced Pluripotent Stem Cells by TALEN and CRISPR-Cas9." Stem Cell Reports 4.1 (2014): 143-54.
description	11.	Doudna, Jennifer A. "The new frontier of genome engineering with CRISPR-Cas9." Science 346.6213 (2014): 96-1258096.
description	12.	Chen, Janice S. "The chemistry of Cas9 and its CRISPR colleagues." Nature Reviews Chemistry 1.10: 78-.
description	13.	Jiang, F. "CRISPR–Cas9 Structures and Mechanisms." Annual review of biophysics 46.1 (2017): 505-529.
description	14.	RATH, D. "The CRISPR-Cas immune system: Biology, mechanisms and applications." Biochimie 117 (2015): 119-128.
description	15.	Waldmann, P. "Concepts And Case Studies In Chemical Biology." Concepts and Case Studies in Chemical Biology. Wiley-VCH,, 2014.
description	16.	Dinsmore, R E. "Vascular calcification in types II and IV hyperlipoproteinemia: radiographic appearance and clinical significance." AJR, American journal of roentgenology (1985): 895-9.
description	17.	Jaenisch, R. "Generating genetically modified mice using CRISPR/Cas-mediated genome engineering." Nature protocols 9.8 (2014): 1956-1968.
description	18.	Sander, Jeffry D. "CRISPR-Cas systems for editing, regulating and targeting genomes." Nature biotechnology 32.4 (2014): 347-355.
description	19.	Cong, David e. "Multiplex Genome Engineering Using CRISPR/Cas Systems." Science 339.6121 (2013): 819-823.
description	20.	Puchta, H. "Applying CRISPR/Cas for genome engineering in plants: the best is yet to come." Current opinion in plant biology 36.C (2016): 1-8.